Adjunctive oral cancer screening systems
This Cigna Coverage Policy governs the coverage position for adjunctive oral cancer screening systems (light-based visualization devices, chemiluminescence devices, lesion marking systems, and related adjunctive tests) as adjuncts to conventional visual and tactile oral examinations, and references laboratory saliva testing guidance separately.
Annual Review dated 01/15/2025: No clinical policy statement changes; hyperlink added for Laboratory Management Clinical Guidelines.
Focused Review dated 11/01/2024: No clinical policy statement changes.
Annual Review dated 12/03/2023: Removed statements on Saliva Testing and oral CDX Brush Biopsy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.